These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11475269)

  • 21. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
    Wolffenbuttel BH; Landgraf R
    Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS; Abrams Z; Lieberman N
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
    Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
    Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
    Moses R
    Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics and pharmacodynamics of repaglinide.
    Hatorp V
    Clin Pharmacokinet; 2002; 41(7):471-83. PubMed ID: 12083976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
    Fang FS; Gong YP; Li CL; Li J; Tian H; Huang W; Wang LC; Li L
    Eur J Endocrinol; 2014 Jun; 170(6):901-8. PubMed ID: 24694876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
    Wang W; Bu R; Su Q; Liu J; Ning G
    Expert Opin Pharmacother; 2011 Dec; 12(18):2791-9. PubMed ID: 21780853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repaglinide.
    Balfour JA; Faulds D
    Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
    Hatorp V; Huang WC; Strange P
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1475-8. PubMed ID: 10199798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
    Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
    Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
    Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
    Mafauzy M
    Diabetes Res Clin Pract; 2002 Oct; 58(1):45-53. PubMed ID: 12161056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
    Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
    Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repaglinide dose response? A clinician's viewpoint.
    Schade DS
    Diabetes Technol Ther; 1999; 1(3):257-8. PubMed ID: 11475270
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
    Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
    Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes.
    Kølendorf K; Eriksson J; Birkeland KI; Kjellström T; Hreidarsson AB
    Diabetes Res Clin Pract; 2004 Apr; 64(1):33-40. PubMed ID: 15036825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.